Covid-19, EU – Baltic States, Good for Business, Legislation, Markets and Companies, Medicine

European Commission President Ursula von der Leyen said last week that EMA might greenlight the vaccines developed by US pharmaceutical giant Pfizer together with German company BionTech and US company Moderna before the end of December.

"It is difficult to predict timelines for the authorization of vaccines precisely at this stage, as the data are still coming in and the rolling reviews are currently ongoing," the European Medicines Agency said in an emailed statement to AFP.

"Depending on how the evaluation progresses, EMA could indeed be in a position to conclude evaluation for the most advanced candidates towards the end of this year or the beginning of next," the regulator said.

The Amsterdam-based EMA is carrying out "rolling reviews" designed to speed up vaccine approval times on three candidates: Pfizer-BioNTech, Moderna, and Oxford University-AstraZeneca.

US giant Pfizer and Germany's BioNTech has already sent data to the EMA after the companies said clinical trials showed their experimental vaccine is 95% effective.

US-based Moderna meanwhile says its vaccine is 94.5 percent effective, and Oxford and AstraZeneca said Monday that theirs showed 70% effectiveness, rising to 90% depending on the type of dosage.

Several European countries have already unveiled strategies to roll out coronavirus vaccines to large parts of their populations as soon as they are approved by the EMA.